|
Disease-management indicators to improve gastric and colorectal cancer control in the Colombian National Health System. |
|
|
No Relationships to Disclose |
|
|
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; CIPLA; Eisai; Fresenius Kabi; Janssen-Cilag; Lilly; Merck Serono; Merck Sharp & Dohme; Novartis; Pfizer; Roche/Genentech; Sanofi |
Consulting or Advisory Role - Bristol-Myers Squibb; Lilly/ImClone; Pfizer |
Research Funding - AstraZeneca; Bristol-Myers Squibb; Eisai; Lilly/ImClone; Merck Sharp & Dohme; Pfizer |
Expert Testimony - Sanofi |
|
Patricia Sánchez Quintero |
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Amgen; AstraZeneca; Bristol-Myers Squibb/Pfizer; Merck; Novartis; Roche |
Speakers' Bureau - Amgen; Bristol-Myers Squibb; Grunenthal; Janssen; Novartis |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |